Market capitalization | $1.68m |
Enterprise Value | $-1.05m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.09 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-17.83m |
Free Cash Flow (TTM) Free Cash Flow | $-11.15m |
Cash position | $2.79m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast PainReform Ltd:
1 Analyst has issued a forecast PainReform Ltd:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.02 -0.02 |
0%
0%
|
|
EBITDA | -18 -18 |
78%
78%
|
EBIT (Operating Income) EBIT | -18 -18 |
78%
78%
|
Net Profit | -18 -18 |
81%
81%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Head office | Israel |
CEO | Ehud Geller |
Employees | 7 |
Founded | 2007 |
Website | www.painreform.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.